Nemes Rush Group’s Akebia Therapeutics AKBA Stock Holding History

Nemes Rush Group’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2	Closed	-$3	–	954
2026 Q1	$3	Buy	+2	New	+$3	﹤0.01%	943

Other funds holding AKBA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nemes Rush Group's AKBA Position: Q2 2026 in Review

Nemes Rush Group sold out of Akebia Therapeutics (AKBA) in Q2 2026, closing a stake of 2 shares — an estimated $3 sold.

Nemes Rush Group first reported a position in AKBA in Q1 2026 and held it in 1 quarter. The position peaked at $3 in Q1 2026. 170 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

Nemes Rush Group reported no remaining Akebia Therapeutics position as of Q2 2026 after selling out during the quarter.
Nemes Rush Group sold 2 Akebia Therapeutics shares in Q2 2026, an estimated $3.
Nemes Rush Group first reported a position in Akebia Therapeutics in Q1 2026 and held it in 1 quarter.
Nemes Rush Group's Akebia Therapeutics position peaked at $3 in Q1 2026.
170 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Nemes Rush Group's 13F filing for Q2 2026, filed 14 Aug 2026.